Regulatory issues

The medical device amendments of 1976 to the Food, Drug and Cosmetic Act created three levels regulation for devices: Class 1, General Controls: meaning that only the general provisions of the Act would be needed by the FDA to control the safety and effectiveness of devices in this class. General controls include premarket notification, good manufacturing practices, truth in labeling, and adequate directions for use. Class 11, Performance Standards: which was later redefined as Special Controls, meaning that the FDA would need to apply special rules for particular devices to assure safety and effectiveness of those devices. The general controls also apply. Class III, Premarket Approval: meaning an application (PMA) to market the device would be submitted to the FDA and that the device could not be marketed unless the application was approved. General controls also apply, and special controls might also apply.

[1]  K. Kraemer,et al.  Normal vitamin D levels can be maintained despite rigorous photoprotection: six years' experience with xeroderma pigmentosum. , 1997, Journal of the American Academy of Dermatology.

[2]  E. Birch,et al.  Impact of Early Dietary Intake and Blood Lipid Composition of Long-Chain Polyunsaturated Fatty Acids on Later Visual Development , 2000, Journal of pediatric gastroenterology and nutrition.

[3]  David Moher,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. , 2003, Clinical chemistry.

[4]  Joseph F. Noferi,et al.  Creating effective biopharmaceutical QA/QC organizations : Your people are the key , 2002 .

[5]  G. FitzGerald,et al.  The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. , 1989, The New England journal of medicine.

[6]  P. Howe Dietary Fats and Hypertension Focus on Fish Oil , 1997, Annals of the New York Academy of Sciences.

[7]  R. Mensink,et al.  Compartmental modeling to quantify alpha-linolenic acid conversion after longer term intake of multiple tracer boluses. , 2005, Journal of lipid research.

[8]  J. L. Dahl,et al.  Pain management, controlled substances, and state medical board policy: a decade of change. , 2002, Journal of pain and symptom management.

[9]  S. Wittenberg Solar radiation and the eye: a review of knowledge relevant to eye care. , 1986, American journal of optometry and physiological optics.

[10]  Grant M. Carrow,et al.  Pain management and prescription monitoring. , 2002, Journal of pain and symptom management.

[11]  Kristin Shrader-Frechette,et al.  Risk analysis and scientific method , 1985 .

[12]  I. Feller,et al.  Scientific and Technological Information in State Legislatures , 1979 .

[13]  E. Schmidt,et al.  Long-term supplementation with n-3 fatty acids, I: Effect on blood lipids, haemostasis and blood pressure. , 1992, Scandinavian journal of clinical and laboratory investigation.

[14]  R. Steinbrook Physician-assisted suicide in Oregon--an uncertain future. , 2002, The New England journal of medicine.

[15]  Dai Fukumura,et al.  Tissue engineering: Creation of long-lasting blood vessels , 2004, Nature.

[16]  A. Gilson,et al.  Pharmacists' knowledge of and attitudes toward opioid pain medications in relation to federal and state policies. , 2001, Journal of the American Pharmaceutical Association.

[17]  M. O'hare,et al.  Searching for Safety , 1990 .

[18]  R. Setlow,et al.  Wavelengths effective in induction of malignant melanoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Roger Clarke Who is liable for software errors? Proposed new product liability law in Australia , 1989, Comput. Law Secur. Rev..

[20]  B. Rumack,et al.  Human overdose with the veterinary tranquilizer xylazine. , 1986, The American journal of emergency medicine.

[21]  H. Olsson,et al.  Risk of cutaneous malignant melanoma in relation to use of sunbeds: further evidence for UV-A carcinogenicity , 2000, British Journal of Cancer.

[22]  U. Wester,et al.  An Analysis of UVA Emissions from Sunlamps and the Potential Importance for Melanoma , 1998, Photochemistry and photobiology.

[23]  C. S. Hill,et al.  Government regulatory influences on opioid prescribing and their impact on the treatment of pain of nonmalignant origin. , 1996, Journal of pain and symptom management.

[24]  P. Whelton,et al.  Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials. , 1993, Archives of internal medicine.

[25]  D. Grobbee,et al.  Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials , 2002, Journal of hypertension.

[26]  M. Law,et al.  Plant sterol and stanol margarines and health , 2000, BMJ : British Medical Journal.

[27]  J C Juskevich,et al.  Bovine growth hormone: human food safety evaluation. , 1990, Science.

[28]  C. J. Louis,et al.  Drug abuse with inhalated xylazine , 2003, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[29]  C. Schroeder Rights Against Risks , 1986 .

[30]  A. Gilson,et al.  Controlled substances and pain management: changes in knowledge and attitudes of state medical regulators. , 2001, Journal of pain and symptom management.

[31]  J. L. Dahl State cancer pain initiatives. , 1993, NIDA research monograph.

[32]  R. Gibson,et al.  A Critical Appraisal of the Role of Dietary Long-Chain Polyunsaturated Fatty Acids on Neural Indices of Term Infants: A Randomized, Controlled Trial , 2000, Pediatrics.

[33]  Xavier Castellsagué,et al.  Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.

[34]  Alan D. Woolf,et al.  Abuse of Telazol: An Animal Tranquilizer , 2001, Journal of toxicology. Clinical toxicology.

[35]  H. Olsson,et al.  Use of sunbeds or sunlamps and malignant melanoma in southern Sweden. , 1994, American journal of epidemiology.

[36]  Paul W. Allen,et al.  Survival guide to FDA inspections. Part 1, To prepare or not to prepare, there is no question , 2002 .

[37]  J. Hansen,et al.  Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. , 1997, The American journal of clinical nutrition.

[38]  Michael J Lysaght,et al.  Tissue engineering: the end of the beginning. , 2004, Tissue engineering.

[39]  D G Altman,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British journal of cancer.

[40]  M. Allman-Farinelli,et al.  Replacement of linoleic acid with α-linolenic acid does not alter blood lipids in normolipidaemic men , 1998, British Journal of Nutrition.

[41]  P. Autier,et al.  Cutaneous malignant melanoma and exposure to sunlamps or sunbeds: An eortc multicenter case‐control study in Belgium, France and Germany , 1994 .

[42]  R Scott Obach,et al.  SEEING THROUGH THE MIST: ABUNDANCE VERSUS PERCENTAGE. COMMENTARY ON METABOLITES IN SAFETY TESTING , 2005, Drug Metabolism and Disposition.

[43]  C. Hertzman,et al.  The association of cutaneous malignant melanoma with the use of sunbeds and sunlamps. , 1990, American journal of epidemiology.

[44]  E. Birch,et al.  Visual Acuity and the Essentiality of Docosahexaenoic Acid and Arachidonic Acid in the Diet of Term Infants , 1998, Pediatric Research.

[45]  Talbot Page,et al.  A Generic View of Toxic Chemicals and Similar Risks , 1978 .

[46]  B. Diffey,et al.  The erythemal response of human skin to ultraviolet radiation , 1985, The British journal of dermatology.

[47]  S. Linder,et al.  Enforcement costs and regulatory reform: The agency and firm response , 1984 .

[48]  T. O'Leary,et al.  Food and Drug Administration regulation of in vitro diagnostic devices. , 2005, The Journal of molecular diagnostics : JMD.

[49]  R. Gregory,et al.  Public perceptions of electric power transmission lines , 1988 .

[50]  B. Rosner,et al.  The effect of fish oil on blood pressure in mild hypertensive subjects: a randomized crossover trial. , 1993, The American journal of clinical nutrition.

[51]  F. Sacks,et al.  Does Fish Oil Lower Blood Pressure? A Meta‐Analysis of Controlled Trials , 1993, Circulation.

[52]  H. Beecher,et al.  Ethics and clinical research. , 1966, The New England journal of medicine.

[53]  Stephen G. Breyer,et al.  Regulation and its reform , 1982 .

[54]  Mackie,et al.  Sunbeds in current use in Scotland: a survey of their output and patterns of use , 1998, The British journal of dermatology.

[55]  M. Weinstock,et al.  Do tanning lamps cause melanoma? An epidemiologic assessment. , 1998, Journal of the American Academy of Dermatology.

[56]  R. Kanner Opioids for severe pain: little change over 15 years. , 2001, Journal of pain and symptom management.

[57]  G. Fritz,et al.  Propofol dependency in a lay person. , 2002, Anesthesiology.

[58]  Sheila Jasanoff,et al.  Risk management and political culture , 1986 .

[59]  T. Brennan,et al.  Legal and scientific probability of causation of cancer and other environmental disease in individuals. , 1985, Journal of health politics, policy and law.

[60]  R. Hendel,et al.  A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. , 2005, Journal of the American College of Cardiology.

[61]  Toshio Shimizu Health claims on functional foods: the Japanese regulations and an international comparison , 2003, Nutrition Research Reviews.